Drugs / CT0890B
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07617285 | May 2026 → Dec 2027 expected | acute myeloid leukemia | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT0890B | “Infusion of CT0890B CAR-T cells at one of four dose levels using an i3+3 Dose-Escalation Design:” NCT07617285 ↗ |
| Modality | Cell therapy | “CT0890B CAR-T cells” NCT07617285 ↗ |